Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Bernadette Pedersen"'
Autor:
Su Yin Lim, Yingxin Lin, Jenny H. Lee, Bernadette Pedersen, Ashleigh Stewart, Richard A. Scolyer, Georgina V. Long, Jean Y.H. Yang, Helen Rizos
Publikováno v:
EBioMedicine, Vol 107, Iss , Pp 105308- (2024)
Summary: Background: Melanoma is a heterogeneous cancer influenced by the plasticity of melanoma cells and their dynamic adaptations to microenvironmental cues. Melanoma cells transition between well-defined transcriptional cell states that impact tr
Externí odkaz:
https://doaj.org/article/0f6bc570850d4b089ffba99d3b6434f7
Autor:
Su Yin Lim, Elena Shklovskaya, Jenny H. Lee, Bernadette Pedersen, Ashleigh Stewart, Zizhen Ming, Mal Irvine, Brindha Shivalingam, Robyn P. M. Saw, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, Georgina V. Long, Helen Rizos
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-18 (2023)
Immunotherapy resistance is common among melanoma patients. Here, the authors identify three resistance mechanism subtypes across tumor-derived cell lines and matched samples and highlight antigen presentation disruption as a key mediator of resistan
Externí odkaz:
https://doaj.org/article/3b0749adf7cc4ff997d621256e99d21e
Publikováno v:
Exploration, Vol 2, Iss 3, Pp n/a-n/a (2022)
Abstract Colorectal cancer (CRC) is the third most diagnosed and the second lethal cancer worldwide. Approximately 30–50% of CRC are driven by mutations in the KRAS oncogene, which is a strong negative predictor for response to anti‐epidermal gro
Externí odkaz:
https://doaj.org/article/4683bbf0309a45f2896f787b7a915f73
Autor:
Jenny H. Lee, Elena Shklovskaya, Su Yin Lim, Matteo S. Carlino, Alexander M. Menzies, Ashleigh Stewart, Bernadette Pedersen, Malama Irvine, Sara Alavi, Jean Y. H. Yang, Dario Strbenac, Robyn P. M. Saw, John F. Thompson, James S. Wilmott, Richard A. Scolyer, Georgina V. Long, Richard F. Kefford, Helen Rizos
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
A significant proportion of patients develop innate or acquired resistance to immune checkpoint inhibitors. Here, the authors show that resistance to anti-PD-1 blockade is associated with TGF-beta driven major histocompatibility complex I (MHCI) down
Externí odkaz:
https://doaj.org/article/ab9ea89ca686469ba37cbf4ad9951d86
Autor:
Gulietta M. Pupo, Suzanah C. Boyd, Carina Fung, Matteo S. Carlino, Alexander M. Menzies, Bernadette Pedersen, Peter Johansson, Nicholas K. Hayward, Richard F. Kefford, Richard A. Scolyer, Georgina V. Long, Helen Rizos
Publikováno v:
Biomarker Research, Vol 5, Iss 1, Pp 1-4 (2017)
Abstract Alternate BRAF splicing is the most common mechanism of acquired resistance to BRAF inhibitor treatment in melanoma. Recently, alternate BRAF exon 4–8 splicing was shown to involve an intronic mutation, located 51 nucleotides upstream of B
Externí odkaz:
https://doaj.org/article/84e147d5245d4efc8c430efe2b83f592
Autor:
Zizhen Ming, Su Yin Lim, Ashleigh Stewart, Bernadette Pedersen, Elena Shklovskaya, Alexander M. Menzies, Matteo S. Carlino, Richard F. Kefford, Jenny H. Lee, Richard A. Scolyer, Georgina V. Long, Helen Rizos
Publikováno v:
Journal of Investigative Dermatology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca5ddcc0f5299be664379403397dc0df
https://doi.org/10.1016/j.jid.2023.01.017
https://doi.org/10.1016/j.jid.2023.01.017
Autor:
Elena Shklovskaya, Bernadette Pedersen, Ashleigh Stewart, Jack O. G. Simpson, Zizhen Ming, Mal Irvine, Richard A. Scolyer, Georgina V. Long, Helen Rizos
Publikováno v:
Cancers; Volume 14; Issue 19; Pages: 4830
Immunotherapy has transformed the management of patients with advanced melanoma, with five-year overall survival rates reaching 52% for combination immunotherapies blocking the cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) and programmed cell d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bd3a90068d2e4f50e594d657aa390d9
Publikováno v:
Pigment Cell & Melanoma Research. 35:471-473
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e40d72805e033f025685dad2a0cc88fd
https://doi.org/10.1111/pcmr.13041
https://doi.org/10.1111/pcmr.13041
Autor:
Carina Fung, Suzanah C. Boyd, Richard A. Scolyer, Peter Johansson, Gulietta M. Pupo, Richard F. Kefford, Nicholas K. Hayward, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Bernadette Pedersen, Helen Rizos
Publikováno v:
Biomarker Research, Vol 5, Iss 1, Pp 1-4 (2017)
Biomarker Research
Biomarker Research
Alternate BRAF splicing is the most common mechanism of acquired resistance to BRAF inhibitor treatment in melanoma. Recently, alternate BRAF exon 4–8 splicing was shown to involve an intronic mutation, located 51 nucleotides upstream of BRAF exon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c696f14a8e5faabc42211aae8120d28a
http://link.springer.com/article/10.1186/s40364-017-0098-3
http://link.springer.com/article/10.1186/s40364-017-0098-3
Autor:
Bernadette Pedersen, Richard F. Kefford, Georgina V. Long, Helen Rizos, Richard A. Scolyer, John F. Thompson, James S. Wilmott, Sara Alavi, Jenny H. Lee, Ashleigh Stewart, Malama Irvine, Alexander M. Menzies, Matteo S. Carlino, Dario Strbenac, Robyn P. M. Saw, Elena Shklovskaya, Jean Yee Hwa Yang, Su Yin Lim
Publikováno v:
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Transcriptomic signatures designed to predict melanoma patient responses to PD-1 blockade have been reported but rarely validated. We now show that intra-patient heterogeneity of tumor responses to PD-1 inhibition limit the predictive performance of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::134ceb102740b038d7bcca6d97ae60e5
https://pubmed.ncbi.nlm.nih.gov/32312968
https://pubmed.ncbi.nlm.nih.gov/32312968